ArticleJournal of cancer research and clinical oncology2023

KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer.

Keitaro Shimozaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.